← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents
lurbinectedin
L01XX69
Forms & Strengths
- 0.25 mg and 1 mg and 4 mg powder for concentrate for solution for infusion
- Intravenous solution
Adult Dosing
- 3.2 mg/m² every 3 weeks
- Dose reduction to 2.6 mg/m² in case of toxicity
Pediatric Dosing
- Safety and efficacy in pediatric patients not established
Indications
- Treatment of adults with unresectable or metastatic liposarcoma who have received prior chemotherapy containing anthracyclines
- Treatment of adults with unresectable or metastatic leiomyosarcoma who have received prior chemotherapy containing anthracyclines
Mechanism of Action
- Inhibits active transcription by binding to DNA
- Induces apoptosis in cancer cells
Contraindications
- Hypersensitivity to lurbinectedin
- Severe neutropenia
- Pregnancy and lactation
Adverse Reactions
- Neutropenia
- Anemia
- Fatigue
- Nausea
- Dyspnea
Drug Interactions
- CYP3A inhibitors may increase lurbinectedin plasma concentrations
- CYP3A inducers may decrease lurbinectedin plasma concentrations
- Concomitant use of lurbinectedin with yellow fever vaccine
Curated Content: Needs Vetting Before Put to Clinical Use